India's Dr Reddy's to manufacture Biosignal's furanones

Sydney-based Biosignal (ASX:BOS) has engaged Custom Pharmaceutical Serivces, a business unit of Indian generics-manufacturing specialist Dr Reddy's Laboratories, to develop a large-scale manufacturing procedure for Biosignal's antibacterial furanone compounds.

Dr Reddy's will then synthesise furanones for use in product development and registration Biosignal's anti-bacterial contact lenses and antifouling paints.

Custom Pharmaceutical Serivces produces cGMP compliant products in ISO certified facilities. Hyderabad-based Dr Reddy's is listed on the NYSE, and is best known for its aggressive pursuit of the generics market, launching numerous patent challenges against big pharma drugs. Its marketing rights for a generic version of Eli Lilly's Prozac ended two years ago. Dr Reddy's is also conducting research into new drugs.